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Abstract
Histone deacetylase inhibitors (HDACi) are a novel class of drugs that target histone
deacetylases, enzymes that by removing acetyl groups from the lysine resides of histones and
many other non-histone proteins alter the cell’s chromatin structure and cellular functions,
including regulation of protein translation and transcript stability. The mechanism of how these
inhibitors destabilize some but not all transcripts remains incompletely understood. Our recent
research has demonstrated that treatment of ERBB2-positive breast cancer cells with the
HDAC1/2 selective HDACi, FK228 (Romidepsin) promotes rapid decay of various oncogenic
mRNA transcripts including ERBB2 mRNA. Most recently we have demonstrated that histone
acetyltransferase p300 (p300 HAT) appears to maintain the stability of ERBB2 mRNA and its
knock-down by siRNA enhances ERBB2 mRNA decay without affecting housekeeping gene
transcripts like GAPDH mRNA. As with FK228 treatment, the potent p300 HAT inhibitor, A485, comparably induces ERBB2 mRNA decay within hours of cell exposure. Given these
findings, we now propose that FK228 and A-485 destabilize ERBB2 mRNA by modulating the
posttranslational acetylation of p300 HAT and known or unknown p300 HAT substrates. To test
this hypothesis we employed mass spectrometry to detect intracellular p300 HAT acetylation,
along with that of other p300-associated proteins, and measured ERBB2 transcript decay by RTPCR following FK228 and A-485 treatment and compared to siRNA knockdown of p300. Our
findings support a new mechanistic model of ERBB2 transcript stability based on p300 and its
acetylation status. We also propose that FK228 and A-485 offer two new drug treatment
approaches for patients with ERBB2-positive breast cancers refractory to current anti-ERBB2
therapeutics, targeting the activation of our newly identified ERBB2 transcript destabilizing
mechanism.
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Introduction
Over the past few decades, researchers have made strides in understanding the molecular
mechanisms driving both development and progression of many different cancers (Heimann and
Hellman, 2000), including breast cancer which in 2012 took the lives of over 40,000 US women
and accounted for 29% of all new female cancer cases (DeSantis et al., 2015). Though significant
progress has been made, a greater understanding of how cancers are able to dysregulate the
pathways crucial to proper cellular development will further accelerate development of cancer
therapeutics and will lead to more specific and effective treatment options.
Breast Cancer Treatments and Subtypes
Breast cancer can be classified into a number of different subtypes, as each subtype has a
distinct molecular signature. Among these subtypes are estrogen receptor (ER)-positive and ERnegative breast cancers (Anderson et al., 2014). The molecular subtype that is driven by
amplification and protein overexpression of the human epidermal growth factor 2 (HER2) gene,
also commonly known as ERBB2, accounts for up to 20% of all breast cancers (Kourie et al.,
2014). ERBB2 mRNA encodes a receptor tyrosine kinase residing on the cell surface whose
overexpression and dysregulated intracellular signaling drives the uncontrolled growth and
proliferation of ERBB2-positive breast cancer cells (Baselga et al., 2017) (Figure 1).
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Figure 1: HER2+/ERBB2+ cell signaling originates from DNA amplification, RNA and protein overexpression of the
ERBB2 oncogene which drives malignant cell growth, motility and invasiveness (Rubin et al., 2001).

For more than two decades, pharmaceutical development of antibodies that specifically
target the overexpressed ERBB2 cell surface receptor, as well as small molecule inhibitors of its
constitutive intracellular kinase activity, have resulted in successful clinical treatment approaches
for patients with either newly diagnosed or metastatic ERBB2-positive breast cancer (Fang et al.,
2014 and Long-Yuan et al., 2011). However, these ERBB2-positive cancers often develop
clinical resistance to these currently available receptor-targeted anti-ERBB2 therapeutics,
necessitating further development of mechanistically novel anti-ERBB2 therapeutics (Dent et al.,
2013 and D’Alessio, et al., 2009), including the repurposing of small molecule drugs that target
either histone acetyl transferases (HATS) or histone deacetylases (HDACS).
HATs and HDACs
HATs and HDACs are essential players in driving the common protein posttranslational
modification known as lysine acetylation. These enzymes are known to primarily modify
chromatin structure by either adding acetyl groups (HATS) or removing acetyl groups (HDACs)
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on histones, thereby regulating the cell’s “epigenetic code;” but they are now also well
recognized for their ability to regulate the acetylation status of various non-histone cytoplasmic
and nuclear proteins. Cancer cells often show dysregulation of their epigenetic code with
changes to their chromatin methylation and acetylation status; for example, total loss of
acetylation on histone (H)-4 at lysine (Lys)-16 and trimethylation at H4 Lys-20 are common in
many human cancers (Fraga et al., 2005). A number of key intracellular proteins besides
histones, including the tumor suppressor protein p53 and the cell structure protein tubulin, also
have their structure and function regulated by the HATs and HDACs (Dingding et. al 2009).
Therefore, these non-histone proteins can also be dysregulated by HATs and HDACs during
cancer development. In some cancers, the overexpression of HDACs has been shown to enhance
the cells’ ability to transcribe and translate mRNA effectively, bolstering their tumorigenic and
angiogenic potential (Li and Seto, 2016 and Ellis, L., 2009). But more information about the
cancer-driving potential of these protein acetylation-regulating enzymes, particularly specific
classes of HDACs, is needed (Drummond et al., 2005 and Eliseeva et al. 2007).
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Figure 2: HDACi screens show downregulation of ERBB2 mRNA compared to GAPDH in SKBR3 breast cancer cells.
The HDAC1/2 class inhibitor, FK228, shows comparable downregulation of ERBB2 mRNA compared to the panclass HDACi, TSA (Alejo and Scott, 2016).

In various cancers, the overexpression of HDACs activates the cellular pathways leading
to tumorigenesis and angiogenesis (Li and Seto, 2016). HATs and HDACs play many roles in
different cell functions and are grouped into different families based on shared homology and
functional domains (Drummond et al., 2005 and Eliseeva et al. 2007). More information about
these enzymes and their roles in cancerous cells is needed in order to improve the potential use
of HAT and HDAC inhibitors as cancer therapeutics. This has been a focus of previous Benz
laboratory studies, including those showing that HDAC class I inhibitors like FK228 are as
effective as as pan-HDACi like trichostatin-A (TSA) in causing the rapid decay of ERBB2
mRNA (Figure 2; Alejo et al., 2016). Recently, a mass spectrometry screen of FK228 induced
acetylated proteins in the ERBB2-positive breast cancer cell line SKBr3 identified p300 to be
acetylated after 4 hours of FK228 treatment (Scott, 2018). The p300 protein is a well-studied
large histone acetyltransferase, primarily localized in the nucleus but also observed in the cytosol
of some breast cancer samples; and in breast cancer models inhibition of the acetylase function
of p300 reduced both breast cancer growth as well as its invasiveness (Fermentoa et al, 2014).
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As a HAT, p300 is often paired with CREB binding protein (CBP) to regulate transcription
factors and increase expression of target genes, including the tumor suppressing protein p53
(Dingding et al., 2009). Members of the very large family of HAT enzymes are classified based
on both their homology structure and catalytic HAT mechanism (Drazic et al., 2016). The ping
pong mechanism used by HATs like the MYST family, and the ternary complex mechanism
used by HATs like the GCN5 family, are two commonly studied acetylation mechanisms (Luo et
al., 2014). The ping pong mechanism is characterized by a covalent interaction between the
acetyl group and the HAT enzyme prior to lysine modification of the target protein. Alternately,
the ternary complex mechanism begins with the simultaneous binding of the cofactor, Acetyl
CoA, and to the HAT substrate followed by an immediate reaction splitting off the acetyl group
from the CoA with covalent binding to the substrate’s lysine residue. The p300/CBP family of
HATs utilize a similar but distinct “hit-and-run” mechanism (Lou et al., 2014). In both the
ternary complex and the hit-and-run reactions a ternary complex is formed to accept and add the
acetyl group from Acetyl CoA to the lysine residue. However, in the hit-and-run mechanism this
ternary complex is much more transient and occurs without the explicit buildup of this complex.
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Figure 3: p300 structure with domain identification. Notable regions include three separate PTM interacting
domains: acetylation recognizing bromodomain followed by an interrupted PHD domain by a RING domain.
Most importantly, the active HAT domain follows the reader domains, and intricate protein folding shows that
these domains tightly regulate binding to the HAT active site (Devecchio, et al., 2013).
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p300 and Breast Cancer
p300 has many distinct roles and acetylation targets and therefore p300 dysregulation has
been linked to many types of malignancies ranging from breast cancer to leukemia (Wang,
Marshall, and Ikura, 2012, Gao et al., 2013). As well as being a HAT, p300 can act as either a
transcriptional corepressor or coactivator, and depending on cancer context it can serve as either
a tumor suppressor or an oncogene (Iyer et al., 2004). Because of this variability in function, it is
crucial to understand how p300 acts under different cellular conditions. One study described
p300 as a corepressor to the c-Myc oncogene (Sakar et al., 2014). This group determined that
p300, in conjunction with HDAC3 and the YY1 protein, was able to repress c Myc transcription.
When endogenous p300 protein function was altered using p300 genetic knockout or domain
specific inhibitors, one group found that p300 performs many more functions than simply
remodeling chromatin including the use of its bromodomain as a “reader” of protein acetyl
groups and E3 ligase activity to add ubiquitin groups to specific proteins (Weinert et al. 2018).
Modulation of p300 activity has been studied as a form of cancer therapy; the p300 HAT domain
inhibitor, A-485, has proven useful in treating certain types of prostate cancer as a way to
regulate androgen receptor activity (Davey and Grossman, 2016). Such drugs as A-485 are also
being used to map the acetylome and to understand disturbances in the acetylome as it occurs in
various disease models. When compared to specific genetic knockouts, A-485 was shown to
most strongly induce loss of H2B acetylation, especially at lysine (K)-15, with fewer acetylation
changes noted on H2A, H3 and H4 (Figure 4; Weinert et. al., 2018).
The Mass Spec Core at the Buck Institute has helped confirm some of these acetylation
site changes by showing that treatment with FK228 induced a quadruple acetylation on H2B and
a triple acetylation on H3. In short, p300 acetylation modifications regulate many aspects of cell
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activity; but with specific regard to the regulation of ERBB2 mRNA stability, the mechanistic
interaction between p300 and HDAC1/2 appears to be most important to account for the similar
transcript destabilizing consequences of A-485 and FK228 treatments.

Figure 4: p300 specific acetylation changes based on various drug treatments including full genetic knockout
and A485 treatment. H2B shows most widespread and dramatic acetylation loss and includes the most intense
loss of acetylation at K15 (Weinert et. al., 2018).

Selective Degradation of Cancerous mRNA
Previous research has suggested that p300 as well as HDAC 1 and 2 inhibition can induce
rapid destabilization of all classes of poly(A) mRNA (Sharma et al., 2016). Another study found
a relationship between transcription and mRNA stability (Shalem et al., 2011). However,
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previous data from the Benz group suggest that HDAC 1 and 2 and p300’s effect on RNA decay
requires specific 3’UTR sequences present in a subset of oncogenic mRNAs like ERBB2 but
does not globally degrade polyA mRNAs or affect transcripts of housekeeping genes like
GAPDH (Scott, 2018). Such discrepancies in the literature underscore the need for greater
understanding of mRNA decay mechanisms and how these might be specifically targeted for
cancer therapy. Another pathway by which a cell is able to respond to various stimuli is by
controlling steady state mRNA levels and thus determining the amount of mRNA available to be
translated into proteins under specific conditions. One of the better understood methods of
mRNA processing is related to its degradation through “decapping complexes” that are able to
remove the stabilizing 5’ cap from the RNA and thus targeting it for degradation (Syntichaki,
2015). mRNA structure also has an effect on translation levels through folding orientation;
recent studies have shown that mRNAs have transient folded forms that influence their ability to
be translated and, much like posttranslational modifications, these folded forms serve to
influence the availability of these transcripts to the ribosomal translation machinery. Likewise,
the discovery of processing bodies and stress granules as major foci of mRNA degradation add
another layer of control to the transcriptome. It is also well documented that alterations to some
of these mRNA complexes are a hallmark for cancer development and reduced life span
(Topisirovic, 2018, Vaskovicova et al., 2017).
Transcript Stability and Degradation Mechanisms
Depending on the structure of the mRNAs that are targeted as well as elements within
their 3’UTR, degradation can occur through several different mechanisms. A well-studied
process of mRNA degradation involves the presence of a premature stop codon which promotes
activation of nonsense-mediated decay complex which initiates 5’-3’ decay via the exonuclease,
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XRN1 (Vaskovicova et al., 2017). In the case of stalled translation, the cell will follow the nogo decay (NGD) pathway. If, on the other hand, the ribosome does not encounter a stop codon,
then the cell will continue with the non-stop decay (NSD) pathway where both of these pathways
conclude with the transcript undergoing 5’-3’ degradation. These degradation pathways also
almost always include “decapping” the mRNA or removing its polyA tail. As noted above, this
decapping process involves removing the 5’ cap by decapping complexes like DCP2 or NUDT16
while polyA tail removal is facilitated by such complexes as PAN2/PAN3. By removing the 5’
cap or polyA tail from the mRNA, the transcript is destabilized and is exposed to other
degradation machinery like the exoribonuclease, XRN1 (Garneau, 2007).
Recent studies show that there are unique structures and processes that help steer
translation machinery away from improperly transcribed mRNAs while simultaneously
degrading them. Some of these structures include processing bodies (PBs) and stress granules
(SGs), which are transient sites for various mRNA processing steps, including degradation
(Topisirovic, 2018). These bodies, mostly located in the cytoplasm, are made up of messenger
ribonucleoproteins (mRNPs) and are assembled by assembly complexes that release the mRNP’s
from the polysome and promote interaction with other freed mRNPs (Erikson and LykkeAndersen, 2011). Enzymes for deadenylation and degradation are used at PB’s, but not SG’s.
Another aspect that helps regulate mRNA is the presence or absence of 3’ folded structures just
upstream of the polyA tails, these short folds in the mRNA chain influence translation machinery
and increase mRNA stability (Topisirovic, 2018).
Yet another method of cellular mRNA control relies on microRNAs (miRs) that
effectively silence transcripts in a posttranslational manner (Ambrose, 2004). These miRNAs are
typically ~22 nt long and will signal for the degradation of the transcripts that they
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complementarily bind to (Bartel, 2004). This allows for more specific control over the
transcriptome and the availability of corresponding mRNA sequences. Naturally, the discovery
of miRs provided an interesting boon to cancer research, especially those with well characterized
transcript targets, like ERBB2-positive breast cancers. Certain miRs like miR-125a/b interact
directly with ERBB2 (Scott, et al 2007), and these miRs can themselves be transcriptionally
regulated by HDAC inhibitors (Scott et al, 2006). Recent experiments performed by the Benz
group have shown that along with miR-125a/b, an mRNA stabilizing protein known as HuR also
binds to the AU-rich region in the 3’UTR of ERBB2 mRNA (Scott et al., 2008).
HuR’s location depends on cell stress. During stressed conditions, like proteasome
inhibition, HuR tends to move out of the nucleus and is ubiquitinated by the E3 ligase, BetaTrCP1, suggesting that HuR is primarily degraded in the cytoplasm (Grammatikakis, 2016).
HuR’s localization is largely controlled using posttranslational modifications like
phosphorylation by various kinases like checkpoint kinase 2 (CHK2) or any number of the
cyclin-dependant kinases. HuR targets a wide variety of mRNA’s primarily by binding to AU
rich elements in the transcript’s 3’UTR and has been implicated in many disease models, but it is
primarily involved in cancer development through stabilization of mRNA linked to
differentiation and proliferation (Grammatikakis, 2016). Specifically for breast cancer, the Benz
laboratory first demonstrated that HuR interacts with the 3’ UTR of ERBB2 mRNA and controls
its stability (Scott et al. 2008). An integrated model of 3’UTR-dependent ERBB2 mRNA
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stability mechanisms in shown below in Figure 5.

Figure 5: Integrated model of 3’UTR-dependent ERBB2 mRNA stability mechanisms. miR-125a/b bind to the
proximal seed sequence in the 3’UTR of ERBB2 mRNA and induce transcript decay. In contrast, HuR binds to the
distal uracil-rich region in the ERBB2 3’UTR and induces transcript stability. Incubating with an HDACi (FK228)
results in the degradation of ERBB2 transcripts.
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Specific Aims
1. Delineate the mechanistic involvement of p300 HAT protein, including its acetylation
status and potential substrate(s), in mediating HDAC1/2-dependent ERBB2 transcript
destabilization by FK228.
a. Characterize formation of multiple <300 kDa immunoreacting isoforms relative to
full-length p300 HAT protein.
b. Compare the effects of p300 siRNA knockdown and p300 protein
hyperacetylation by HDAC1/2 inhibitor FK228 on p300 HAT activity and total
intracellular ERBB2 mRNA and protein levels.
c. Evaluate HAT domain-specific p300 inhibitors for their abilities to reduce
ERBB2 mRNA and protein levels relative to p300 siRNA knockdown or p300
hyperacetylation by FK228.
2. Develop an integrated mechanistic model of ERBB2 transcript stabilization and decay,
and identify the most promising pharmacologic strategy to induce ERBB2 mRNA decay
and treat ERBB2-positive breast cancers.
a. Compare HDAC1/2 inhibitor FK228 with p300 HAT inhibitor A485 to identify
the most efficient pharmacologic means of inducing ERBB2 mRNA decay.
b. Evaluate targeting of the FK228-induced p300 HAT enzymatic product, acH2BUb, for its involvement in contributing to FK228-induced ERBB2 mRNA decay
c. Demonstrate co-dependence of FK228 and A485 induction of ERBB2 mRNA
decay on ERBB2 mRNA 3’UTR sequences and its binding to the transcript
stabilizing protein, HuR
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Methods
Cell Maintenance
The SKBR3 cells were cultured in McCoy’s 5A, 1X with L-glutamine media with 10%
FBS as suggested by the ACTCC. Cells were originally placed in a Corning 75cm2 Cell Culture
Flask and were maintained biweekly by aspirating the old media, and washing with 2mL of
DPBS without calcium and magnesium. After washing with DPBS the cells were trypsinized
using 2mL of 0.05% Trypsin, 0.53 mM EDTA, 1X without sodium bicarbonate. The cells were
incubated at 37°C for 2 minutes. The cells were visualized to ensure they were floating in the
flask before resuspending them with 10mL of new McCoy’s media. Cells are stored in an
incubator at 37°C until needed for plating or the next maintenance.
Cell Harvest
When cells reached 85% confluency in the maintenance flask, they were trypsinized and
resuspended in media as mentioned above, and 2mL aliquot was plated in each well of a CellStar
Sterile 6 Well Culture Dish. These cells were allowed to settle over a 24hr period, drugged with
FK or A485 as described below if needed, and harvested in .3mL 2xSDS. Cells were then
sonicated for 10 seconds.
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Bortezomib Treatments
Treatment with the anti-cancer drug, Bortezomib, began with an established 6 well dish
as mentioned above. Using adhered cells, a mixture of .1µM Bortezomib and fresh McCoy’s
Media was prepared. The old media was aspirated and replaced by 2mL of the drugged media.
Bortezomib was allowed to incubate in the dishes for up to 10hrs and harvested as described
above.
SiRNA Treatments
P300 siRNA was purchased from Dharmacon. Prior to use, oligos were resuspended in
MiliQ water to a 20 µM concentration. Then, two separate solutions of 150 µL of Optimedium
were prepared. 9 µL of RNAMax was added to one solution and 1.5 µL of the siRNA is added to
the other. The solutions were combined and allowed to incubate for about 15 minutes. The
mixture was added to a six well dish and then media was added until a final volume of 2mL is
reached. The cells were incubated for 48-72 hours, harvested and visualized using western
blotting with a p300 specific antibody to check the success of the knockdown.
FK228 and A-485 Treatments
Using adhered cells, as generated above, a mixture of .5 µM of FK228, A-485, or a
combination of both and fresh McCoy’s Media with 10% FBS was prepared. The old media was
aspirated and replaced by 2mL of the media containing drug. The inhibitors, HDACi, FK228, or
p300 inhibitor, were allowed to incubate in the dishes for up to 6 hours and harvested as
described above.
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mRNA Isolation
mRNA isolation began with established SKBR3 cells plated on 6 well dishes. The plated
cells were washed with sterile PBS and harvested in .4mL Trizol. Phases were separated by
adding .8µL chloroform and centrifuging samples in the Eppendorf 5425 centrifuge for 5
minutes at 12,000 rcf. The aqueous layer was removed and placed in a separate tube. RNA was
precipitated by adding 200 µL isopropanol. The tube was inverted and incubated at room
temperature for 10 minutes. The sample was then centrifuged again for 12 minutes at 13,500 rcf
in the cold room. The supernatant was removed and the sample was allowed to air dry for about
2 minutes. The pellets were then resuspended in 30µL DEPC water and tested for quality on the
Nanodrop ND 1000.
RT-PCR
A master mix of oligo dT with 250µM dNTP and DEPC water was created. Into new
tubes, 1 µL of Nuclease free water and 12 µL of the master mix was added, and 500ng/ml RNA,
then mixed and spun down. The mixture was allowed to incubate at 65C° for 5 minutes then
placed on ice for 1 minute. Next, .1M DTT, RNAse Out and Superscript III RT were added. The
samples were incubated at 50 C° for 45 minutes and then at 70C° for 15 minutes. Then, .04 µL
25mM dNTPs, 10 µL 5x Phusion Buffer (New England Biotech), .5 µL 50mM forward and
reverse primers (ERBB2 and GAPDH) (Table X), and 37.5 µL DEPC water. 48.5 µL of this
mixture was placed in a separate tube with 1 µL of cDNA and kept on ice. Finally, .5 µL of Pfu
Polymerase was added to each tube. The Applied Biosystems Thermocycler was programmed at
22 cycles beginning with 95 C° for 1 minute, (95 C° for 15s., 70 C° for 20s., 72 C° for 20s.,) 72
C° for 1 minute and 4 C° to end.
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To visualize the results of the PCR, an 8% TBE gel was run using 5X TBE buffer (27g
Tris-Base, 13.75g boric acid, 2.34g EDTA and 450ml of Millipore water) diluted to 1X in
200mL Millipore water. 10 µL of sample was loaded along with 4 µL of DNA loading buffer.
The gel was run for 30 minutes at 200v, stained for 2 minutes using EtBr, washed in water for at
least 10 minutes, and visualized on the Bio-Rad Gel Doc™ XR+ Molecular Imager.
Gel Electrophoresis, Western analysis and Immunoassays
Gel electrophoresis and Western blot analysis was performed to size separate and then
detect specific proteins using various antibodies. Densitometry was used to quantify
autoradiographic band intensity. Cell lysate samples were run on a Novex™ NuPAGE™ 3-8%
Tris Acetate Protein Gel (Invitrogen™ Carlsbad, CA) using molecular weight markers
(Amersham Full-Range RainbowTM Recombinant Protein (GE Healthcare, San Ramon, CA)
and transferred to Immobilon® - P nitrocellulose membrane (MilliporeSigma, St. Louis, MO).
The membrane was blocked with 4% non-fat dry milk in 1X TBST (Tris Buffer Saline with
Tween 20), incubated with primary antibody (Table1) for 1 hour in the case of p300 specific
antibodies and overnight in the case of the Acetylated Lysine antibody, washed three times with
1X TBST, incubated with goat anti-rabbit IgG secondary antibody conjugated to horse radish
peroxidase (HRP) (0.1µL/mL) for one hour, and washed three times with 1X TBST before
incubating it with SuperSignal® West Pico Stable Peroxide Solution and West Pico
Luminol/Enhancer Solution (Thermo Scientific). Chemiluminescent signal was captured on film
and developed with Konica SRX-101A Medical Film Processor (Konica Corporation, Taiwan).
Images were analyzed using ImageJ FIJI software (US National Institutes of Health, Bethesda,
MD) and the area corresponding to each band of interest was quantified. Relative protein levels
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were calculated by taking the intensity of each band minus the background intensity and
compared to β-actin and α-tubulin total protein intensity.
Laser Confocal Imaging Protocol & Immunocytochemistry Assays
Cells were imaged using a Zeiss LSM 780 confocal microscope (Zeiss, Dublin, CA) with
constant temperature enclosure and CO2 regulation using 63X oil magnification in all
experiments. SKBR3 cells were plated in 4-well glass slides from Lab-Tek®II (MilliporeSigma,
St. Louis, MO) where one chamber was left for negative control to be treated with secondary
antibody only and one chamber for an untreated control condition. The other two wells were
treated with either .1mM FK228 or .5mM Bortezomib for 5 hours. Cells on slides were fixed
with 4% paraformaldehyde in PBS (VWR, Radnor, PA) and blocked with 0.35% IGEPAL® CA630 NP 40 (MilliporeSigma, St. Louis, MO) diluted to 10% in DEPC water, mixed with 7%
normal goat serum (Cell Signaling Technologies, Danvers, MA) in PBS. Next, cells were probed
with a variety of primary antibodies overnight and secondary antibodies for 90 minutes (Alexa
mouse and rabbit). ProLong® Gold antifade reagent with DAPI (Molecular Probes by Life
Technologies, Thermo Fisher Scientific, Carlsbad, CA) was used to stain for the nuclei of cells
for 24 hours before imaging at 63X oil magnification. Bitplane Imaris Software (Oxford
Instruments, Concord, MA) used for 3D or 4D reconstruction and analysis of fixed and
functional imaging data.
Sypro Ruby Staining and Mass Spectrometry Preparation
Gels prepared for Mass Spec analysis were stained using Sypro Ruby and visualized on a
Bio-Rad Gel Doc™ XR+ Molecular Imager. Gels were run similarly to the western blot
protocols above. However, for staining, a Novex™ NuPAGE™ 4-12% Bis Tris gel was used.
Sypro Ruby staining was preformed according to ThermoFisher’s protocol. First, the gels were
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fixed via 2 rounds of 100mL fixing solution (50% methanol, 7% acetic acid) for 30 minutes each
on the orbital shaker. The fixing solution was replaced with the Sypro Ruby stain and
microwaved for 30 seconds, agitated for 30 seconds to disperse heat and stain, and reheated for
30 more seconds in the microwave. The stain was then incubated on the orbital shaker for 5
minutes and reheated again for 30 seconds. After the final microwaving step, the gel was allowed
to incubate on the orbital shaker for 25 more minutes. The gel was then washed with a washing
solution (10% methanol, 7% acetic acid) for 30 minutes. One more rinsing step in pure water
was required before visualization. Proteins of interest were visualized, cut out and digested by
the Mass Spec Core.
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Antibody
P300 358
P300 CT (D8Z4E)
P300 NT (D1M7C)
P300 Leu 733(D2X6N)
AC LYS
Alpha-Tubulin (Ab-1)
ERBB2
UPA (h-140)
HDAC1 (10E2)
HDAC2 (3F3)
HUR
H2BK5 (D5H1S)
H2BK12 (D7H4)
H2BK20
Ub H2B (D11)

Company
Bethyl
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling
Oncogene
Calbio Chem
Santa Cruz Biotech
Cell Signaling
Cell Signaling
Santa Cruz Biotech
Cell Signaling
Cell Signaling
Cell Signaling
Cell Signaling

Table 1: Antibodies Used

Primers
GAPDH forward
GAPDH reverse

Sequence
TGACAACTTTGGTATCGTGGAAGG
AGGCAGGGATGATGTTCTGGAGAG

ERBB2 forward
ERBB2 reverse

CTCGTCTGCCCCCTGCAAACC
GGAGCTGCTCTGGCTGGAGCGG

Table 2: Primer Sequences

ID
A300-358A
86377s
70088S
54062S
9814s
cp06-100ug
OP15
sc-14019
5356S
5113S
sc-5261
12790T
9861S
2571S
5546T

LOT
1
1
1
5
D10362-6
D00122957
L0805
4
1
DO618
1
1
1
6
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Results
p300 Full-length Protein and Proteolytic Isoforms (Aim 1a.)
We have shown that p300 is proteolytically processed at multiple sites. All blots were run
using 3-8% Tris Acetate gels for consistency in comparing bands at higher molecular weights.
By comparing and contrasting the western blot bands produced by the various p300 site specific
antibodies, we identified and mapped five proteolytic sites resulting in six distinct isoforms. All
antibodies used were able to detect the “full length” p300 protein at 300 kDa as well as the
largest fragmented isoform at approximately 200 kDa (Figure 6). Detection of the various
fragments running at molecular weights below the 200 kDa fragment was dependent upon the
p300 antibody used (Figure 6B, C). The C- Terminus antibody (Cell Signaling) was able to
detect all of the various p300 fragments (Figure 6A). This antibody detects a protein residue
within the last 400 amino acids of the p300 sequence. The other three antibodies are probing for
the N terminus (Cell Signaling), Leucine 733 (Cell Signaling) and a Bethyl Labs antibody
probing a 50 amino acid sequence at ~950-1000 amino acids within p300. Using these four p300
specific antibodies in combination with p300 siRNA we were able to confirm that the five
isoforms of p300 originated from p300 mRNA with their molecular weights determined from
western blotting to be 175kDa, 160kDa, 120kDa, and two separate 100kDa fragments, one on
each terminus (Figure 6). Interestingly, the proposed proteolytic sites were closely centered on
the highly acetylated HAT domain of p300 located between amino acids 1300-1600 (Figure 7).
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A)

B)

Figure 6: p300 proteolytic fragments detected by different p300 antibodies on 3-8% Tris-Acetate gels. Nonspecific signals in each antibody were controlled using p300 siRNA. A) The Bethyl 358 p300 antibody recognized
200kDa and 150kDa acetylated bands. B) Leucine 733 antibody probed fragments at all molecular weights.
Acetylated Lysine showed acetylated p300 isoforms: all previously confirmed p300 isoforms were acetylated
except the 175 kDa isoform and the 100 kDa isoform.
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Figure 7: Map of p300 proposed proteolytic sites based on molecular weights of identified isoforms. Cuts
assume that p300 was being cleaved in one spot only.

Determining Acetylation Status of Individual p300 Isoforms (Aim 1a.)
To help elucidate the relationship between acetylation and p300 processing, we wanted to
determine which p300 isoforms were acetylated. This was accomplished with an Acetylated
Lysine antibody and p300 siRNA. Acetylated bands were present in the acetylated antibody plus
siRNA treatment indicating that there were other acetylated proteins in the sample (Figure 6).
The majority of the p300 fragments were shown to be acetylated after FK treatment. However,
the fragments at 100kDa were not acetylated. There is an acetylation signal closely linked to the
100kDa p300 fragment, but the FK treated p300 siRNA samples have equal signal as the FK
treated control samples suggesting that the acetylated band is not from p300.
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Bortezomib Treatments Modulate p300 Isoform Levels (Aim 1a.)
To elucidate the mechanism of p300 processing we tested multiple inhibitors to various
classes of proteases, but none of them promoted a decrease in the expression of the p300
fragments by western analysis (data not shown). Experiments with proteasomal inhibitors were
then undertaken to determine if the proteasome was the source of p300 processing. To this end,
we treated cells with the proteasomal inhibitor Bortezomib at 0.1 µM and harvested cells at
different time points over a 10 hour period (Figure 8). These preliminary experiments showed
that the processing of p300 still occurred with p300 fragments detectable even at the 10 hour
time point. However, there was a buildup of the full length p300 suggesting that the proteasome
had been deactivated and any new p300 produced would not be processed in this way.
Interestingly, the Benz laboratory has previously shown that proteasomal inhibition is also
implicated in the degradation of ERBB2 mRNA (Scott, et. al., 2008).

P300/Actin

.22

.16

.19

.51

.6

Figure 8 : Full length p300 protein builds up after 7 hours of Bortezomib treatment. Full length p300 detected
using a C Terminus antibody (Cell Signaling). Protein amounts were quantified and compared against β Actin
using Image J.
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Figure 9: Acetylation Western blot showed differing acetylation patterns under different p300 modulating drugs.
Treatment with 6 hours of p300 active domain inhibitor, A485, reduced acetylated bands on Western blot
including full length p300. Treatment with an HDACi, FK228, increased documented acetylation at 220 kDa and
increased full length p300 signal.

FK228 Treatment Reduces Total p300 Protein (Aim 1b.)
Continuing the study of p300 modulation, we wanted to understand how these
drugs affected total p300 levels over time. To accomplish this, we ran a 3-8% Tris Acetate gel
similar to the mapping experiments above using control lysates, and A485/FK treated lysates.
Using a p300 antibody (Bethyl 358) probing for the middle of the protein, we found that under
both conditions, the level of full length p300 is decreased compared to control (Figure 10). The
full length p300 band was normalized against tubulin and decreased most drastically by the HAT
inhibitor A485 at both the 3 hour and 6 hour time point.
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Figure 10: 3-8% Tris-Acetate gel with FK228, A-485 and untreated samples at 3 and 6 hour time point normalized
to tubulin. Both drug treatments show a decrease in full length p300 at the 6 hour time point, however, the A485 also shows a significant decrease at the 3 hour time point.

28 kDa Acetylated Protein Identified as H2B (Aim 2b.)
While examining p300 acetylation with Western Blotting, we found an acetylated band
around 28kda in FK228 treated samples only (Figure 11 A). Further experimentation with p300
siRNA demonstrated that this 28kDa acetylated band was dependent upon p300 (Figure 11 B).
An antibody specific to an Ac K5 H2B showed a significant downregulation of this 28kDa band
following FK228 treatment of SKBR3 p300 siRNA cells. We also noticed that the addition of
Bortezomib, both before and after FK228 treatment, suppressed the appearance of this 28kDa
acetylated band. A gel was run with samples containing the 28kDa band and after staining with
Sypro Ruby, the 28 kDa fragment was cut out of a gel and sent to the Mass Spec Core for
identification. Interestingly, H2B was identified and found to be acetylated on multiple lysines
under FK228 treatment (Figure 11).
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A)

28

B)

Figure 11: 4-12% agar Western blots probed with A) Acetylated Lysine and B) AcK5 H2B under various
conditions. siRNA experiments were controlled with nonspecific siRNA treatments denoted as siC and are
treated with FK or Bortezomib (B) as indicated. FK treated samples in both blots show an acetylated band
around 28kDa that is downregulated when treated with p300 siRNA or Bortezomib.

Monoubiquitinated H2B Found in Acetylation Blots (Aim 2b.)
Once the 28 kDa protein was identified as H2B by mass spec analysis, we wanted to
understand why it was running as a 28kDA protein on our Western blots compared to the
standard ~17 kDa molecular weight for histone H2B. We probed with a monoubiquitinated H2B
antibody and found that the monoubiquitinated H2B ran precisely at 28kDa (Figure 12A). As
noted earlier, Bortezomib suppressed the 28kDa band. Shown data corroborate the report that
Bortezomib inhibits the monoubiquitination of H2B, (Xu Q et al., 2004). Next, we treated cells
with siRNA to the E3 ligase responsible for monoubiquitination, RNF20, to elucidate how this
particular reaction might influence the appearance of the 28kDa species and ERBB2 decay. We
found that the RNF knockdown blunted the expression of the acetylated upper band at 28kDa,
but H2B acetylation remained similar to that of control FK228 treated cells. Finally, we
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performed RTPCR using various siRNAs to determine which would most dramatically reduce
ERBB2 mRNA levels (Figure 12C). Using untreated SKBR3 cells as a control, we determined
that RNF20 knockdown did not significantly reduce control ERRB2 mRNA levels, however,
RNF20 knockdown did appear to decrease the effectiveness of FK treatment on inducing ERBB2
mRNA decay. p300 knockdown was the most effective at reducing ERBB2 mRNA especially
when combined with a 6 hour FK pretreatment.

A)

B)
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C)

Figure 12: A) Western blot probed with a monoubiquitinated H2B antibody shows treatment with Bortezomib
blocks monoubiquitination. B) siRNA experiments for RNF20 and p300 show varying effectiveness at blocking
monoubiquitinated species of H2B when probed with H2BK5. Untreated siRNF samples show total
downregulation of monoUbH2B, but unmodified H2B remained similar to control levels. P300 knockdown was
most effective at decreasing expression of both species and FK treatments across the samples slightly rescued
this downregulation. C) RTPCR of ERBB2 transcripts compared to GAPDH under RNF20 siRNA and p300 siRNA.
P300 knockdown produced most notable degradation, but RNF knockdowns reduced effectiveness of FK
treatment.

Confirming Acetylation Patterns of Specific H2B Residues (Aim 2b.)
To confirm site specific acetylation of histone residues we ran 4-12% NuPage western
blots. The westerns were then probed with acetylation specific antibodies for various histones.
Because H2B separates on a western blot at 17kDa, we anticipated that there would be a double
structure to the acetylation probed western blot with a dominant signal at 17kDa and decreased
signal from monoubiquitinated H2B at 28kDa. For these experiments, cells were treated for 6
hours with either FK or A485, both alone and with Actinomysin D to determine its effects on
p300 acetylation. On all H2B residues: K5(Figure 12A), K12, and K20(Figure 13A,B), FK
increased the signal of these acetylated species compared to control by about 33% on K12 and
90% on K20. A485 decreased the signal compared to control by about 90% on both K12 and
K20. Similarly, cotreatment with Actinomysin D reduced band intensity across all samples when
compared to their single drug treatment counterparts. Interestingly, the monoubiquitinated
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species were also decreased with A485 treatment and increased with FK treatment. To show
p300 specificity towards H2B, we also ran sip300 samples and probed with an H2AZ antibody
(Figure 13C). This blot showed that under FK treatment the H2AZ signal increased regardless of
the p300 knockdown.

A)

B)
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C)

H2AZ

Figure 13: Western blots using 4-12% gels to determine site specific acetylation under different conditions. A) A
H2BK12 antibody was used; B) A H2BK20 antibody was used. Treatment with FK increased signal compared to
control, while A485 treatment decreased signal compared to control. In both trials, cotreatment with
Actinomysin D reduced signal when compared to control and to the single drug trials. C) A H2AZ antibody was
used to rule out p300’s interaction with H2AZ using both siRNA treated samples and FK228 treatments. FK228
treatment increased H2AZ signal in both sip300 and siC lanes. The intensities are not significantly affected by
p300 knockdown.

p300 and HuR localization (Aim 2c.)
To determine if p300 co-localized with mRNA stabilizing protein, HuR, HER2+ (SKBR3
and BT20) cells were plated on chamber slides and incubated with primary antibodies for both
the C terminus of p300 (Cell Signaling) and HuR (Santa Cruz Biotech) overnight. Following
washing, the slides were incubated with fluorescent secondary antibodies (Alexa 555 and Alexa
488) and examined using a Zeiss 780 inverted confocal microscope. The expression of both p300
and HuR overlaps with the nuclear DAPI staining, but HuR was also detected showing a light
cytoplasmic localization around the nucleus in SKBR3 cell lines. There was no significant
colocalization between p300 and HuR even though they both were mainly located in the nucleus.
The lack of yellow punctate in the merge section indicated that the specific protein punctate were
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not close enough together to implicate significant colocalization under untreated conditions
(Figure 14). Image J colocalization analysis confirmed that there was no significant overlapping
of punctate.

A)
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B)

Figure 14: Determining the localization of p300 and HuR in two cell lines. A) Confocal imaging of SKBR3 cells
probed with HuR in green, p300 in red, and DAPI in blue. P300 localization is totally nuclear, but HuR also has a
light cytoplasmic expression. HuR is absent in the nucleoli, while some p300 punctate is observed there. B)
Confocal imaging of BT cells probed as described in A. p300 and HuR localizations are primarily nuclear, but
again, p300 punctate is seen in nucleoli whereas HuR is not.

p300 modulation Induces ERBB2 mRNA Decay (Aim 1c.)
ERBB2 mRNA was measured under multiple conditions using RTPCR and normalized
using GAPDH mRNA levels as a control. Further experimentation using the p300 siRNA
showed that pretreatment with FK228 would also increase the decay of ERBB2 transcripts to
70% reduction after 6 hours (Figure 15B). Under 6 hours FK treatment, ERRB2 mRNA levels
were reduced by approximately 25% the level of the untreated samples (Figure 15C). Treatment
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with the p300 active site inhibitor, A485, showed similar results reducing ERBB2 mRNA levels
by approximately 40%.

A)

B)

Figure 15: RTPCR data showing ERBB2 degradation compared to GAPDH A) RTPCR of sip300 samples both
untreated and with 6 hours of FK treatment. sip300 in combination with FK produced most intense degradation
of ERBB2 mRNA compared to GAPDH. B) RTPCR of SKBR3 cells under different drug treatments. Both A485 and
FK treatments showed a decrease in ERBB2 mRNA compared to GAPDH, but A485 showed the largest decrease.
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Discussion
We set out to examine how p300 modulation plays a role in the processing and decay of
ERBB2 transcripts and to determine how p300 might best be modulated in order to develop a
new anti-ERBB2 therapeutic strategy. To this end we examined multiple aspects of this multifaceted protein. p300 processing was confirmed using multiple antibodies that probe separate
sites along the p300 protein.
p300 Processing and Fragment Analysis
Using western analysis, p300 siRNA as well as FK treated cell lysates produced a map of
the p300 processing sites where nonspecific antibody bands could be eliminated by comparison
with p300 siRNA lanes. We confirmed five separate fragments using this method, the largest
being 225kDa. Acetylation status of each isoform was confirmed using an Acetylated Lysine
antibody as well as p300 siRNA, both untreated and FK228 treated samples were used. There
were only two known unacetylated p300 isoforms, the 100kDa and the 190kDa. In reference to
the proteolytic map (Figure 7), these unacetylated fragments are small enough to fall outside of
the KAT domain where the most commonly acetylated lysines are located. However, they may
contain other modifications, as they will contain portions of other p300 functional domains. p300
is known to have multiple functionalities including E3 and E4 ligase activity through a ring
finger domain and a reader bromo-domain, either of which could be playing a larger role in
promoting p300 processing (Weinert et al., 2018). The separate p300 domains are not well
characterized and their activities as independent enzymes when processed in this way needs
further study. However, p300 auto-acetylation is well documented (Weinert et. al., 2018) and this
processing may play a part in auto-activation activity, even in the presence of a proteasome
inhibitor. Treatment with Bortezomib shows a slight decrease in the full length p300 at a 2 hour
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time point, but buildup of the full length after 7 hours of treatment suggesting the halt of
processing of full length p300. Presumably, larger fragments are acetylated because they all
contain the HAT domain and are able to auto acetylate in this manner. Another aspect of p300 is
the recently established protein dimerization, which also contributes to this auto acetylation
(Ortega, et. al, 2018).
p300 Modulation and Interactivity
P300 modulation using A485 to inhibit the HAT domain and FK228 to induce its
acetylation following inhibition of HDAC 1/2 proteins has also revealed multiple p300
interacting acetylated lysines on H2B. The implications of these specific lysine residues carrying
acetyl groups needs further study, notably, H2BK5ac has been implicated in regulating multiple
cellular functions and often appears in cancer models as cells make the transition from epithelial
cells to mesenchymal cells (Mobley and Abell, 2017). However, we have confirmed that they are
tightly regulated by p300 and respond to p300 modulation. We also confirmed an interesting
monoubiquitinated species of H2B using an siRNA to the E3 ligase responsible for
monoubiquitination. The described ERBB2 RT PCR experiments showed that blocking H2B
monoubiquitination in this way did not significantly degrade ERBB2 transcripts. Rather, it
slightly impaired FK228 induced ERRB2 mRNA decay; therefore, we believe that this block of
H2B monoubiquitination demonstrates that there are likely other proteins working in conjunction
with p300 and are playing a role in regulating ERBB2 mRNA stability.
To determine if p300 and HuR interact directly, we performed some IF experiments in
two separate ERBB2+ cell lines, SKBR3 and BT474. Confocal images paired with ImageJ
analysis showed no significant overlap of p300 and HuR in either cell line, there are also no
documented interactions between the two proteins in databases like BioGrid and UniProt.
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However, because these proteins are quite ubiquitous and the absence of reported data is not
proof of an absent interaction, some overlap in p300 and HuR co-localization on the 3’UTR of
ERBB2 may still occur. More experiments are needed looking specifically at ERBB2 transcripts
(e.g. RNA FISH) to determine if HuR and p300 are functionally interacting to regulated ERBB2
mRNA stability. To this end, we hypothesize that, as HuR provides mRNA stability, the
modulation of p300 may cause HuR to disassociate from the 3’UTR of the ERBB2 transcript
inducing ERBB2 decay.
ERBB2 Transcript Decay
RT-PCR of SKBR3 cells shows that treatment with the HDAC1/2 inhibitor, FK228,
drastically reduces the amount of ERBB2 mRNA relative to GAPDH mRNA levels. p300 HAT
activity and its many downstream acetylation targets, including H2B, are shedding light on this
complex mechanism of ERBB2 decay. The degradation of ERBB2 mRNA has been observed
following cell treatment with multiple p300 altering drugs. As stated above, FK228 induces the
rapid decay of ERBB2 mRNA. P300 knockdown via siRNA has also been shown to degrade
ERBB2 mRNA, more so when combined with an FK228 treatment. Most interestingly, however,
is the observation that treatment with the p300 HAT domain inhibitor, A485, also produces rapid
decay of ERBB2 mRNA levels. We hypothesize that both increases and decreases to the normal
acetylation patterns of p300 promote a pathway converging on ERBB2 transcript decay. Since
total p300 levels are reduced following treatment with either A485 and FK228, it is also likely
that loss of p300 protein in addition to either its hypo-acetylation by A485 or its hyperacetylation by FK228 are contributing factors destabilizing ERBB2 mRNA and opening it up to
degradation.
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Acetylation altering therapeutics have shown promise in many different aspects of cancer
progression. The pan-class HDACi TSA has been shown to re-sensitize previously resistant cell
lines to existing drugs like doxorubicin (Ponnusamy et al., 2018). Previous Benz laboratory
experiments have shown that treatment with the class-specific HDAC1/2 inhibitor, FK228, is
even more potent than TSA at promoting ERBB2 transcript decay (Scott, unpublished data).
Other proteins besides p300 are most certainly also involved in regulating ERBB2 mRNA
stability, and we have shown using knockdown studies that not only is the acetylation of
monoubiquitinated H2B regulated by p300, its absence also affects the destabilization of ERBB2
induced by FK228. Reducing the total level of p300 protein with FK228, siRNA treatments, or
inhibiting its activity using A485 have all shown promise in destabilizing and reducing the
amount of ERBB2 mRNA. In our current speculative mechanistic model, the role of p300 in
stabilizing ERBB2 mRNA is shown operating within the 3’UTR of ERBB2; we also try to
incorporate other known 3’UTR interacting proteins like HuR in this model (Figure 16).
However, as more information on the targets of p300 acetylation are uncovered and tested for
their ability to affect either FK228 or A484 induction of ERBB2 mRNA destabilization, our
model will likely need to be updated. But, even with our newly discovered role for p300 is
regulating ERBB2 mRNA stability, we now provide cancer experimental therapies with much
needed new drug options, namely FK228 and A485, for the treatment of clinically refractory
ERBB2-positive breast cancers.
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Figure 16: Potential mechanistic hypothesis for ERBB2 instability when treating with either FK228 or A485.
Depicts an mRNA stabilizing complex located on the ERBB2 transcript that is disrupted when p300 is brought out
of its basal levels of acetylation activity.

Future Directions
We described multiple methods to decrease ERBB2 transcripts by modulating p300 and
have shown that altering p300 away from its basal acetylation functions is enough to cause this
decay. More experiments are needed to clarify which aspect of p300 modulation is causing the
most prominent decay. Currently, treatment with siRNA for p300 combined with FK228
treatment provided the most dramatic degradation of ERBB2 as described by RTPCR. The exact
nature of this destabilization must be studied further because FK was shown to decrease total
p300 levels similarly to siRNA treatments. Is it this reduction of total p300 that is causing the
decay or is the combination so effective because the p300 that remains becomes hyperacetylated
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with FK treatment? This can be addressed with more confocal microscopy, visualizing p300 in
the four different treatments, siRNA, FK228, A485 relative to untreated cells. Finally, an
experiment to further illuminate the relationship between HuR and p300 is needed. RNA FISH
with labeled ERBB2 transcripts will help show where and how often these three crucial cellular
components come together. The light colocalization seen in Figure 15 might be heavily centered
on the labeled transcripts and in that case, these proteins are much more closely related than
previously described.
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Conclusion
After experimenting with multiple methods of p300 modulation, the targeted response of
ERBB2 mRNA decay shows that p300 HAT inhibition with A485 is the single most efficient
means of inducing ERBB2 degradation. In terms of combined treatment approaches, however,
treating with FK228 in combination with p300 siRNA knockdown, produced the greatest overall
reduction in ERBB2 mRNA (relative to GAPDH). However, the clinical use of FK228 is not
well tolerated and is associated with many unwanted side effects; likewise there are no small
molecule drugs currently available to simulate complete knockdown of p300 protein, although
the p300 HAT domain inhibitor A485 appears to be an excellent surrogate for inducing ERBB2
mRNA decay. Because A485 is a bioavailable small molecule that in animal studies appears to
be far better tolerated than FK228, we believe that A485 is currently the most efficient and
clinically practical p300 inhibiting drug candidate for moving forward into in vivo preclinical
development as a much needed new treatment modality against clinically refractory metastatic
ERBB2-positive cancer.
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Appendix 1: Mass spectrometry data showing an increase in nuclear H2B acetylation with FK
treatments.
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Appendix B
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Appendix B: Mass spectrometry data showing acetylated proteins and specific
acetylation sites in FK treated samples.
Accessions
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P49327|FAS_HUMAN
sp|P06733|ENOA_HUMAN
sp|P04075|ALDOA_HUMAN
sp|Q09472|EP300_HUMAN
sp|Q09472|EP300_HUMAN
sp|Q09472|EP300_HUMAN
sp|Q09472|EP300_HUMAN
sp|Q09472|EP300_HUMAN
sp|Q09472|EP300_HUMAN
sp|Q09472|EP300_HUMAN
sp|Q09472|EP300_HUMAN
sp|P14618|KPYM_HUMAN
sp|P14618|KPYM_HUMAN
sp|Q5VTE0|EF1A3_HUMAN;
sp|P68104|EF1A1_HUMAN
sp|Q5VTE0|EF1A3_HUMAN;
sp|P68104|EF1A1_HUMAN
sp|Q5VTE0|EF1A3_HUMAN;
sp|P68104|EF1A1_HUMAN
sp|P40926|MDHM_HUMAN
sp|P40926|MDHM_HUMAN
sp|P40926|MDHM_HUMAN

Protein Modifications
Acetyl(K)@1239
Acetyl(K)@772
Acetyl(K)@1582
Acetyl(K)@673
Acetyl(K)@70
Acetyl(K)@787
Acetyl(K)@1911
Acetyl(K)@1072
Acetyl(K)@1065
Acetyl(K)@786
Acetyl(K)@298
Acetyl(K)@436
Acetyl(K)@1704
Acetyl(K)@126
Acetyl(K)@14
Acetyl(K)@1542; Acetyl(K)@1546
Acetyl(K)@1542; Acetyl(K)@1546;
Acetyl(K)@1549
Acetyl(K)@1546; Acetyl(K)@1549;
Acetyl(K)@1550
Acetyl(K)@1674
Acetyl(K)@1551; Acetyl(K)@1554;
Acetyl(K)@1555; Acetyl(K)@1558
Acetyl(K)@1542; Acetyl(K)@1546;
Acetyl(K)@1549; Acetyl(K)@1550
Acetyl(K)@1760
Acetyl(K)@1554; Acetyl(K)@1555;
Acetyl(K)@1558; Acetyl(K)@1560
Acetyl(K)@498
Acetyl(K)@66
Acetyl(K)@179
Acetyl(K)@44
Acetyl(K)@392
Acetyl(K)@301
Acetyl(K)@335
Acetyl(K)@307
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sp|P40926|MDHM_HUMAN
sp|Q92793|CBP_HUMAN
sp|Q92793|CBP_HUMAN
sp|Q92793|CBP_HUMAN
sp|Q92793|CBP_HUMAN
sp|Q92793|CBP_HUMAN
sp|Q92793|CBP_HUMAN
sp|Q92793|CBP_HUMAN
sp|Q92793|CBP_HUMAN
sp|P02768|ALBU_HUMAN
sp|Q93079|H2B1H_HUMAN
sp|Q93079|H2B1H_HUMAN
sp|Q93079|H2B1H_HUMAN
sp|Q93079|H2B1H_HUMAN
sp|Q93079|H2B1H_HUMAN
sp|P62805|H4_HUMAN
sp|P62805|H4_HUMAN
sp|P62805|H4_HUMAN
sp|P62805|H4_HUMAN
sp|P22392|NDKB_HUMAN
sp|P61604|CH10_HUMAN
sp|P13639|EF2_HUMAN
sp|P09622|DLDH_HUMAN
sp|P35579|MYH9_HUMAN
sp|P34897|GLYM_HUMAN
sp|P34897|GLYM_HUMAN
sp|P34897|GLYM_HUMAN
sp|O43809|CPSF5_HUMAN
sp|Q86UU0|BCL9L_HUMAN
sp|P42765|THIM_HUMAN
sp|P49411|EFTU_HUMAN
sp|P19338|NUCL_HUMAN
sp|P12532|KCRU_HUMAN
sp|P53004|BIEA_HUMAN
sp|P23526|SAHH_HUMAN
sp|P30044|PRDX5_HUMAN

Acetyl(K)@297
Acetyl(K)@1605; Acetyl(K)@1606
Acetyl(K)@1583; Acetyl(K)@1586
Acetyl(K)@1583; Acetyl(K)@1586;
Acetyl(K)@1587
Phosphoglyceryl(K)@1587;
Acetyl(K)@1595; Acetyl(K)@1597
Acetyl(K)@1591; Acetyl(K)@1592;
Acetyl(K)@1595; Acetyl(K)@1597
Acetyl(K)@1595; Acetyl(K)@1597
Phosphoglyceryl(K)@1591;
Acetyl(K)@1595; Acetyl(K)@1597
Phosphoglyceryl(K)@1592;
Acetyl(K)@1595; Acetyl(K)@1597
Acetyl(K)@426
Acetyl(K)@13; Acetyl(K)@16;
Acetyl(K)@17; Acetyl(K)@21
Acetyl(K)@6
Acetyl(K)@12; Acetyl(K)@13; Acetyl(K)@16
Acetyl(K)@12; Acetyl(K)@13;
Acetyl(K)@16; Acetyl(K)@17
Acetyl(K)@16; Acetyl(K)@17; Acetyl(K)@21
Acetyl(K)@6; Acetyl(K)@9; Acetyl(K)@13
Acetyl(K)@6; Acetyl(K)@13; Acetyl(K)@17
Acetyl(K)@13; Acetyl(K)@17
Acetyl(K)@6; Acetyl(K)@9; Acetyl(K)@13;
Acetyl(K)@17
Acetyl(K)@124
Acetyl(K)@70
Acetyl(K)@272
Acetyl(K)@420
Acetyl(K)@1441
Acetyl(K)@469
Acetyl(K)@464
Acetyl(K)@103
Acetyl(K)@23
Acetyl(K)@108; Acetyl(K)@110
Acetyl(K)@137
Acetyl(K)@418
Acetyl(K)@79
Acetyl(K)@337
Acetyl(K)@269
Acetyl(K)@408
Acetyl(K)@118
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sp|Q9NPJ3|ACO13_HUMAN
sp|Q9H1E3|NUCKS_HUMAN
sp|Q9H1E3|NUCKS_HUMAN
sp|P61978|HNRPK_HUMAN
sp|P61978|HNRPK_HUMAN
sp|P07954|FUMH_HUMAN
sp|P07954|FUMH_HUMAN
sp|P52565|GDIR1_HUMAN
sp|P07195|LDHB_HUMAN
sp|P24752|THIL_HUMAN
sp|P01106|MYC_HUMAN
sp|P26641|EF1G_HUMAN
sp|P00505|AATM_HUMAN
sp|P12004|PCNA_HUMAN
sp|Q9NR19|ACSA_HUMAN
sp|Q01813|PFKAP_HUMAN
sp|P50990|TCPQ_HUMAN
sp|P62807|H2B1C_HUMAN;
sp|P57053|H2BFS_HUMAN;
sp|O60814|H2B1K_HUMAN
sp|P62807|H2B1C_HUMAN;
sp|P57053|H2BFS_HUMAN;
sp|O60814|H2B1K_HUMAN
sp|P09972|ALDOC_HUMAN
sp|Q96JC9|EAF1_HUMAN
sp|P40939|ECHA_HUMAN
sp|Q9Y3I0|RTCB_HUMAN
sp|Q9UPN9|TRI33_HUMAN
sp|Q9UNL4|ING4_HUMAN
sp|Q9HB07|MYG1_HUMAN
sp|Q96N67|DOCK7_HUMAN
sp|Q8N4M7|CJ126_HUMAN
sp|P61956|SUMO2_HUMAN
sp|P35914|HMGCL_HUMAN
sp|P04040|CATA_HUMAN
sp|P49773|HINT1_HUMAN
sp|P17987|TCPA_HUMAN
sp|Q13564|ULA1_HUMAN

Acetyl(K)@127
Acetyl(K)@184
Acetyl(K)@35
Acetyl(K)@163
Acetyl(K)@34; Deamidated(R)@35
Acetyl(K)@292
Acetyl(K)@80
Acetyl(K)@178
Acetyl(K)@7
Acetyl(K)@174
Acetyl(K)@148
Acetyl(K)@434
Acetyl(K)@363
Acetyl(K)@80
Acetyl(K)@418
Acetyl(K)@688
Acetyl(K)@400

Acetyl(K)@13; Acetyl(K)@16; Acetyl(K)@17
Acetyl(K)@13; Acetyl(K)@16;
Acetyl(K)@17; Acetyl(K)@21
Acetyl(K)@147
Acetyl(K)@150
Acetyl(K)@406
Acetyl(K)@496
Acetyl(K)@763
Acetyl(K)@127; Acetyl(K)@129
Acetyl(K)@40
Acetyl(K)@1962
Acetyl@132; Acetyl(K)@142
Acetyl@2; Acetyl(K)@5
Acetyl(K)@48
Acetyl(K)@237
Acetyl(K)@21
Acetyl(K)@400
Acetyl@2; Acetyl(K)@6

